AXQ Capital’s Zevra Therapeutics ZVRA Stock Holding History

AXQ Capital’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-15,317	Closed	-$135K	–	867
2025 Q2	$135K	Buy	+15,317	New	+$124K	0.04%	495

Other funds holding ZVRA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AXQ Capital's ZVRA Position: Q3 2025 in Review

AXQ Capital sold out of Zevra Therapeutics (ZVRA) in Q3 2025, closing a stake of 15,317 shares — an estimated $135K sold.

AXQ Capital first reported a position in ZVRA in Q2 2025 and held it in 1 quarter. The position peaked at $135K in Q2 2025. 166 funds tracked by Wall St. Rank hold ZVRA as of Q3 2025.

AXQ Capital reported no remaining Zevra Therapeutics position as of Q3 2025 after selling out during the quarter.
AXQ Capital sold 15,317 Zevra Therapeutics shares in Q3 2025, an estimated $135K.
AXQ Capital first reported a position in Zevra Therapeutics in Q2 2025 and held it in 1 quarter.
AXQ Capital's Zevra Therapeutics position peaked at $135K in Q2 2025.
166 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2025.

Based on AXQ Capital's 13F filing for Q3 2025, filed 10 Nov 2025.